There's no EDTA, no fragrance, and a minimal base that lets the active do its work without interference
Peptides like BPC-157 target tissue repair rather than symptom masking
Whether its the shortage, side effects, lack of insurance, or high out-of-pocket costs that prompt patients to stop taking GLP-1 drugs like Ozempic, they all face the same issue: how to maintain the results they got from the drug after they stop taking it, says Robert Kushner, MD, a professor and the director of the Center for Lifestyle Medicine at Northwestern University Feinberg School of Medicine in Chicago
Top companies in the market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi and AstraZeneca North America dominated the market in 2024, holding the largest revenue share of 68.4%
From 175 per single chin session, delivered only by qualified clinicians, across our seven UK clinics